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Background: Impact of chronic anti-coagulation (CAC) for concurrent indications on mortality in patients with Heart Failure with Preserved 
Ejection Fraction (HFPEF) is not known.
Methods: From Jan 2000 to June 2011, 17617 consecutive patients at Montefiore Medical Center with HFPEF (ejection fraction >50% with grade 
2-4 diastolic dysfunction and clinical presentation of heart failure) were included. Patients not on CAC due to any contraindication to CAC were 
excluded. Baseline comparisons were performed using standard parametric and non-parametric tests. Adjusted Hazard Ratios (HR) was estimated 
using multiple Cox proportional hazard models. Model 1 was unadjusted, Model 2 was only adjusted for demographics and Model 3 was additionally 
adjusted for clinical data (see table legend).
Results: On an average, patients were 71 years old, 40% men and 29% were white. Median follow up was 4.7 years. Furthermore, 60% patients in 
the cohort were on CAC (40% for atrial fibrillation (afib) and CHADS2 >2, 8% for mechanical valve, 5% for severe pulmonary hypertension and 15% 
for other thromboembolic disorders). Overall, patients on CAC were less likely to die (HR: 0.84, 95% CI: 0.76 -0.93) compared to those not on CAC. 
However, no difference in mortality was noted in those on CAC for afib compared to those not on CAC for afib (see table for additional results).
Conclusion: HFPEF patients on chronic anti-coagulation for a concurrent indication were noted to live longer compared to those not on chronic 
anti-coagulation.
 
